Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

NCT04133155 · clinicaltrials.gov ↗

COMPLETED

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions

DRUG: nab paclitaxel plus gemcitabine

Sponsor

Asan Medical Center

Collaborators

[object Object]
[object Object]